Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by LENZ Therapeutics, Inc.

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
From Lenz Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
Tickers LENZ
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
Tickers LENZ
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
From LENZ Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.